Guidelines from the National Comprehensive Cancer Network® recommend tamoxifen or aromatase inhibitors as endocrine treatments for postmenopausal women diagnosed with early oestrogen receptor-positive (ER+) breast cancer (39). This evidence concerns the gene CYP19A1 and breast carcinoma.